Cargando…

Efficacy and safety of de-escalation bone- modifying agents for cancer patients with bone metastases: a systematic review and meta-analysis

BACKGROUND: Compared with application of bone-modifying agents (BMAs) every 4 weeks, it is unclear whether 12-weekly de-escalated therapy can be used as a substitute strategy. METHODS: A systematic search of PubMed, EMBASE, and the Cochrane Register of Controlled Trials until November 22, 2017, was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Cun, Wang, Lu, Liu, Lijuan, Zhuang, Jing, Tang, Shifeng, Zhang, Tiansong, Zhou, Chao, Feng, Fubin, Liu, Ruijuan, Zhang, Jinmei, Zhang, Tingting, Gao, Chundi, Li, Huayao, Li, Jia, Sun, Changgang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159799/ https://www.ncbi.nlm.nih.gov/pubmed/30288112 http://dx.doi.org/10.2147/CMAR.S176811

Ejemplares similares

SNP mutation‐related genes in breast cancer for monitoring and prognosis of patients: A study based on the TCGA database
por: Gao, Chundi, et al.
Publicado: (2019)

Gene signatures of 6-methyladenine regulators in women with lung adenocarcinoma and development of a risk scoring system: a retrospective study using the cancer genome atlas database
por: Gao, Chundi, et al.
Publicado: (2021)

Development of a risk scoring system for evaluating the prognosis of patients with Her2-positive breast cancer
por: Gao, Chundi, et al.
Publicado: (2020)

7-lncRNA Assessment Model for Monitoring and Prognosis of Breast Cancer Patients: Based on Cox Regression and Co-expression Analysis
por: Li, Huayao, et al.
Publicado: (2019)

Tumor Mutation Burden and Immune Invasion Characteristics in Triple Negative Breast Cancer: Genome High-Throughput Data Analysis
por: Gao, Chundi, et al.
Publicado: (2021)

Cryptotanshinone Is a Intervention for ER-Positive Breast Cancer: An Integrated Approach to the Study of Natural Product Intervention Mechanisms
por: Li, Huayao, et al.
Publicado: (2021)

Identifying the Antiproliferative Effect of Astragalus Polysaccharides on Breast Cancer: Coupling Network Pharmacology With Targetable Screening From the Cancer Genome Atlas
por: Liu, Cun, et al.
Publicado: (2019)

Identifying the Effect of Ursolic Acid Against Triple-Negative Breast Cancer: Coupling Network Pharmacology With Experiments Verification
por: Zhang, Yubao, et al.
Publicado: (2021)

Exploration of methylation-driven genes for monitoring and prognosis of patients with lung adenocarcinoma
por: Gao, Chundi, et al.
Publicado: (2018)

Survival-Associated Metabolic Genes and Risk Scoring System in HER2-Positive Breast Cancer
por: Gao, Chundi, et al.
Publicado: (2022)

Comprehensive Analysis of Gene Signatures of m6ARNA Methylation Regulators in Lung Adenocarcinoma and Development of a Risk Scoring System
por: Gao, Chundi, et al.
Publicado: (2022)

Construction and Analysis of Competing Endogenous RNA Networks for Breast Cancer Based on TCGA Dataset
por: Wang, Xue, et al.
Publicado: (2020)

Natural compounds: Wnt pathway inhibitors with therapeutic potential in lung cancer
por: Shen, Xuetong, et al.
Publicado: (2023)

Identification of key candidate genes and miRNA-mRNA target pairs in chronic lymphocytic leukemia by integrated bioinformatics analysis
por: Gao, Chundi, et al.
Publicado: (2019)

Determination of Genetic and Epigenetic Modifications-Related Prognostic Biomarkers of Breast Cancer: Genome High-Throughput Data Analysis
por: Gao, Chundi, et al.
Publicado: (2021)

Immunogenomic landscape analyses of immune molecule signature-based risk panel for patients with triple-negative breast cancer
por: Liu, Cun, et al.
Publicado: (2022)

The Modulatory Properties of Astragalus membranaceus Treatment on Triple-Negative Breast Cancer: An Integrated Pharmacological Method
por: Liu, Cun, et al.
Publicado: (2019)

Deciphering the mechanism of Indirubin and its derivatives in the inhibition of Imatinib resistance using a “drug target prediction-gene microarray analysis-protein network construction” strategy
por: Li, Huayao, et al.
Publicado: (2019)

Identification of key candidate targets and pathways for the targeted treatment of leukemia stem cells of chronic myelogenous leukemia using bioinformatics analysis
por: Li, Huayao, et al.
Publicado: (2019)

The construction and analysis of ceRNA networks in invasive breast cancer: a study based on The Cancer Genome Atlas
por: Gao, Chundi, et al.
Publicado: (2018)

Exploring the Mechanism of Danshen against Myelofibrosis by Network Pharmacology and Molecular Docking
por: Li, Jie, et al.
Publicado: (2018)

Deciphering Key Pharmacological Pathways of Qingdai Acting on Chronic Myeloid Leukemia Using a Network Pharmacology-Based Strategy
por: Li, Huayao, et al.
Publicado: (2018)

A Novel Glycolysis-Related Four-mRNA Signature for Predicting the Survival of Patients With Breast Cancer
por: Zhang, Xiaolu, et al.
Publicado: (2021)

A Systems Biology-Based Approach to Uncovering Molecular Mechanisms Underlying Effects of Traditional Chinese Medicine Qingdai in Chronic Myelogenous Leukemia, Involving Integration of Network Pharmacology and Molecular Docking Technology
por: Zhou, Chao, et al.
Publicado: (2018)

Target Analysis and Mechanism of Podophyllotoxin in the Treatment of Triple-Negative Breast Cancer
por: Zhang, Wenfeng, et al.
Publicado: (2020)

The Mechanism of Quercetin in the Treatment of Lung Squamous Cell Carcinoma Based on a Protein-Protein Interaction Network
por: Lu, Yiping, et al.
Publicado: (2022)

Combinatorial regimens of chemotherapeutic agents: A new perspective on raising the heat of the tumor immune microenvironment
por: Liu, Jingyang, et al.
Publicado: (2022)

From tumor mutational burden to characteristic targets analysis: Identifying the predictive biomarkers and natural product interventions in cancer management
por: Liu, Cun, et al.
Publicado: (2022)

Identification of lncRNAs associated with lung squamous cell carcinoma prognosis in the competitive endogenous RNA network
por: Qi, Lingyu, et al.
Publicado: (2019)

Combination of Bone-Modifying Agents with Immunotarget Therapy for Hepatocellular Carcinoma with Bone Metastases
por: Chen, Zhaoyu, et al.
Publicado: (2022)

Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey
por: AlZahrani, Mashari, et al.
Publicado: (2020)

Integrated analysis of co‐expression and ceRNA network identifies five lncRNAs as prognostic markers for breast cancer
por: Yao, Yan, et al.
Publicado: (2019)

Post-Translational Modifications of cGAS-STING: A Critical Switch for Immune Regulation
por: Yu, Yang, et al.
Publicado: (2022)

Efficacy and safety of targeted therapy for metastatic HER2-positive breast cancer in the first-line treatment: a Bayesian network meta-analysis
por: Feng, Fubin, et al.
Publicado: (2019)

Multicenter study on atypical femoral fractures in patients with bone metastases taking bone- modifying agents
por: Fukui, Tomoaki, et al.
Publicado: (2023)

The association between statin use and endometrial cancer survival outcome: A meta-analysis
por: Li, Jia, et al.
Publicado: (2018)

Clinicopathological characteristics and prognostic value of the cancer stem cell marker ALDH1 in ovarian cancer: a meta-analysis
por: Zhao, Wenge, et al.
Publicado: (2018)

Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases
por: Addison, Christina L, et al.
Publicado: (2014)

Tumor Characterization in Breast Cancer Identifies Immune-Relevant Gene Signatures Associated With Prognosis
por: Li, Jie, et al.
Publicado: (2019)

Radiation therapy combined with bone-modifying agents ameliorates local control of osteolytic bone metastases in breast cancer
por: Tanaka, Hidekazu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_56viegqlsu44gkqhh1c5c7tatk